Capricor Therapeutics faces a securities class action lawsuit alleging materially misleading statements regarding clinical trial data for its lead drug candidate deramiocel. The company's stock crashed 64% after FDA briefing documents revealed undisclosed modifications to the statistical analysis plan for the HOPE-3 study, which failed to meet pre-specified primary and secondary efficacy endpoints. Investors with losses between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Capricor Therapeutics for allegedly making misleading statements about its Deramiocel drug's regulatory prospects. The company allegedly failed to disclose changes to its statistical analysis plan and lack of FDA agreement before resubmitting the Biologics License Application. Capricor's stock plummeted 64% on July 27, 2026, after the FDA released unfavorable briefing documents, and fell an additional 36% on July 30, 2026, following an AdCom panel's 9-3 vote against the drug's efficacy. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible to participate in the class action lawsuit, with a September 28, 2026 deadline to seek lead plaintiff status.

Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics for making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of non-approval. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.

A class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan for clinical data without FDA approval before resubmitting its Biologics License Application, creating significant risk of regulatory rejection. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 are eligible to join the lawsuit.

A class action lawsuit has been filed against Capricor Therapeutics on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for its lead drug candidate Deramiocel without FDA approval, leading to FDA concerns about the validity of clinical results. Following FDA briefing documents released on July 27, 2026, Capricor's stock fell 64%, and after an advisory committee voted 9-3 against the drug's efficacy on July 30, the stock fell an additional 36%.

Hagens Berman has expanded a securities fraud class action lawsuit against Pentair plc, alleging the company made materially false statements about its financial health and channel inventory from March 11, 2025 to July 14, 2026. On July 14, 2026, Pentair shocked investors with a massive revenue miss ($930M vs. $1.14B forecast), revealed $170M in Pool segment inventory destocking, slashed full-year guidance, and announced the sudden departure of its CFO after only four months. The stock plummeted 15% the following day. Investors with substantial losses have until October 2, 2026 to become lead plaintiffs.

Hagens Berman notifies Capricor Therapeutics investors of a September 28, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges the company made materially false statements about clinical trial data for its drug deramiocel, failing to disclose undisclosed changes to the statistical analysis plan. After the FDA revealed the HOPE-3 study did not meet pre-specified endpoints, Capricor's stock crashed 64% on July 27, 2026.

Kahn Swick & Foti, LLC announces a class action securities lawsuit against Capricor Therapeutics for failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased shares between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.

Law firm Kirby McInerney LLP is alerting investors about pending securities fraud class action lawsuits against Capricor Therapeutics, Rackspace Technology, and Bloom Energy. The primary focus is on Capricor, which faces allegations of making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA subsequently rejected the drug, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 30, 2026. The lead plaintiff deadline is September 28, 2026.

Law firm Kirby McInerney LLP announced pending securities class action lawsuits against Bloom Energy Corporation for allegedly making false statements about its reliance on Chinese scandium supplies. A short-seller report on July 8, 2026 revealed that Bloom Energy sourced scandium from China through intermediaries despite claiming minimal China supply chain dependence, causing the stock to fall 5.7%. The firm is seeking lead plaintiffs with a September 28, 2026 deadline.

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its Deramiocel cell therapy between December 2025 and July 2026. The FDA's briefing documents criticized the company's statistical analysis methods, and an advisory panel voted 9-3 against the therapy's efficacy, causing the stock to plummet 62% on July 27, 2026. Investors who purchased shares during the class period are urged to file claims by September 28, 2026.

Rosen Law Firm reminds investors in Capricor Therapeutics, Inc. (CAPR) of the September 28, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Capricor made false statements regarding changes to statistical analysis plans for its Deramiocel treatment without FDA approval, creating substantial risk of regulatory rejection and misleading investors about the company's prospects.